- Home
- MRLN vs SLS Comparison
MRLN vs SLS Comparison
Compare MRLN & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRLN | SLS |
|---|---|---|
| Founded | 2018 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 915.1M | 924.5M |
| IPO Year | 2024 | 2007 |
Fundamental Metrics
Financial Performance| Metric | MRLN | SLS |
|---|---|---|
| Price | $7.24 | $8.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $25.00 | $10.00 |
| AVG Volume (30 Days) | 1.7M | ★ 10.1M |
| Earning Date | 10-28-2021 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $110.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.78 | $1.39 |
| 52 Week High | $17.00 | $9.51 |
Technical Indicators
Market Signals| Indicator | MRLN | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 42.95 | 59.65 |
| Support Level | $6.07 | $3.72 |
| Resistance Level | $8.59 | N/A |
| Average True Range (ATR) | 0.95 | 0.88 |
| MACD | 0.13 | 0.05 |
| Stochastic Oscillator | 45.55 | 59.66 |
Price Performance
Historical ComparisonAbout MRLN Merlin Inc. Common Stock
Merlin Inc is focused on developing autonomous flight software for legacy and next-generation airborne systems. Its aircraft-agnostic, AI-based software supports takeoff-to-landing autonomous operations for military and civil aviation programs. The company aims to build an AI-based operating software platform intended to support autonomous flight operations across a range of aircraft types.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.